IPP

Summary

IPP (intracisternal A particle-promoted polypeptide, HGNC:6108) is a protein-coding gene on chromosome 1p34.1, encoding Actin-binding protein IPP (Q9Y573). May play a role in organizing the actin cytoskeleton.

The protein encoded by this gene is a member of the kelch family of proteins, which is characterized by a 50 amino acid repeat which interacts with actin. Transcript variants have been described but their full-length nature has not been determined.

Source: NCBI Gene 3652 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 99 total
• MANE Select transcript: NM_005897

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6108
Approved symbol	IPP
Name	intracisternal A particle-promoted polypeptide
Location	1p34.1
Locus type	gene with protein product
Status	Approved
Aliases	KLHL27
Ensembl gene	ENSG00000197429
Ensembl biotype	protein_coding
OMIM	147485
Entrez	3652

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000359942, ENST00000396478, ENST00000461718, ENST00000495072, ENST00000890995, ENST00000890996, ENST00000890997, ENST00000964613, ENST00000964614

RefSeq mRNA: 2 — MANE Select: NM_005897 NM_001145349, NM_005897

CCDS: CCDS30702, CCDS44132

Canonical transcript exons

ENST00000396478 — 9 exons

Exon	Start	End
ENSE00001401957	45716895	45717017
ENSE00001403014	45719203	45719340
ENSE00001403751	45740901	45741332
ENSE00001404314	45729614	45729769
ENSE00001406047	45727631	45727798
ENSE00001456717	45714246	45714466
ENSE00001456719	45746120	45746461
ENSE00001809958	45750597	45750653
ENSE00001874727	45698711	45700190

Expression profiles

Bgee: expression breadth ubiquitous, 273 present calls, max score 90.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.9167 / max 56.1089, expressed in 1618 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12156	2.5856	1432
12157	0.8744	391
12155	0.4567	178

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	90.12	gold quality
nipple	UBERON:0002030	89.54	gold quality
ventricular zone	UBERON:0003053	87.71	gold quality
renal medulla	UBERON:0000362	86.50	gold quality
pylorus	UBERON:0001166	86.16	gold quality
biceps brachii	UBERON:0001507	86.01	gold quality
hindlimb stylopod muscle	UBERON:0004252	85.97	gold quality
cardia of stomach	UBERON:0001162	85.83	gold quality
superior surface of tongue	UBERON:0007371	85.76	gold quality
mucosa of paranasal sinus	UBERON:0005030	85.60	gold quality
bronchial epithelial cell	CL:0002328	85.50	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.33	gold quality
penis	UBERON:0000989	85.11	gold quality
trigeminal ganglion	UBERON:0001675	85.11	gold quality
adrenal tissue	UBERON:0018303	84.85	gold quality
muscle of leg	UBERON:0001383	84.58	gold quality
trachea	UBERON:0003126	84.53	gold quality
islet of Langerhans	UBERON:0000006	84.44	gold quality
subthalamic nucleus	UBERON:0001906	84.27	gold quality
gastrocnemius	UBERON:0001388	84.14	gold quality
muscle organ	UBERON:0001630	83.92	gold quality
body of tongue	UBERON:0011876	83.92	gold quality
dorsal root ganglion	UBERON:0000044	83.66	gold quality
pericardium	UBERON:0002407	83.57	silver quality
corpus epididymis	UBERON:0004359	83.52	gold quality
inferior vagus X ganglion	UBERON:0005363	83.46	gold quality
cranial nerve II	UBERON:0000941	83.44	gold quality
adult organism	UBERON:0007023	83.43	gold quality
ganglionic eminence	UBERON:0004023	83.29	gold quality
ventral tegmental area	UBERON:0002691	83.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.98

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

56 targeting IPP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-3618	99.69	68.57	1012
HSA-MIR-1251-3P	99.64	67.21	1408
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-4489	99.50	65.56	785
HSA-MIR-6513-5P	99.43	67.81	1071
HSA-MIR-3692-5P	99.29	67.04	1421

Literature-anchored findings (GeneRIF, showing 2)

• Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival. (PMID:32592097)
• MicroRNA-Dependent Targeting of RSU1 and the IPP Adhesion Complex Regulates the PTEN/PI3K/AKT Signaling Pathway in Breast Cancer Cell Lines. (PMID:32751711)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ipp	ENSMUSG00000028696
rattus_norvegicus	Ipp	ENSRNOG00000016183

Paralogs (54): KLHL13 (ENSG00000003096), KLHL20 (ENSG00000076321), KEAP1 (ENSG00000079999), KLHL42 (ENSG00000087448), KLHL22 (ENSG00000099910), KLHL4 (ENSG00000102271), KLHL2 (ENSG00000109466), KLHL5 (ENSG00000109790), BACH2 (ENSG00000112182), KLHL18 (ENSG00000114648), KLHL24 (ENSG00000114796), IVNS1ABP (ENSG00000116679), KLHL12 (ENSG00000117153), KLHL29 (ENSG00000119771), KBTBD7 (ENSG00000120696), KLHL7 (ENSG00000122550), KLHL31 (ENSG00000124743), KLHDC7B (ENSG00000130487), KLHL36 (ENSG00000135686), KLHL8 (ENSG00000145332), KLHL3 (ENSG00000146021), KLHL35 (ENSG00000149243), KLHL1 (ENSG00000150361), BACH1 (ENSG00000156273), KLHL40 (ENSG00000157119), KLHL10 (ENSG00000161594), KLHL21 (ENSG00000162413), KLHDC8A (ENSG00000162873), KBTBD8 (ENSG00000163376), KBTBD6 (ENSG00000165572), KLHL26 (ENSG00000167487), KLHL30 (ENSG00000168427), KBTBD2 (ENSG00000170852), KLHL6 (ENSG00000172578), KLHL15 (ENSG00000174010), KLHL38 (ENSG00000175946), KBTBD11 (ENSG00000176595), KLHDC7A (ENSG00000179023), KLHL28 (ENSG00000179454), KBTBD3 (ENSG00000182359)

Protein

Protein identifiers

Actin-binding protein IPP — Q9Y573 (reviewed: Q9Y573)

Alternative names: Intracisternal A particle-promoted polypeptide, Kelch-like protein 27

All UniProt accessions (1): Q9Y573

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in organizing the actin cytoskeleton.

Subcellular location. Cytoplasm. Cytoskeleton.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y573-1	1	yes
Q9Y573-2	2

RefSeq proteins (2): NP_001138821, NP_005888* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR006652	Kelch_1	Repeat
IPR011043	Gal_Oxase/kelch_b-propeller	Homologous_superfamily
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR011705	BACK	Domain
IPR015915	Kelch-typ_b-propeller	Homologous_superfamily
IPR017096	BTB-kelch_protein	Family
IPR030104	BTB_POZ_IPP	Domain
IPR047067	IPP_BACK	Domain

Pfam: PF00651, PF01344, PF07707, PF24681

UniProt features (10 total): repeat 6, chain 1, domain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y573-F1	90.12	0.70

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 142 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, MODULE_511, BLALOCK_ALZHEIMERS_DISEASE_UP, chr1p34, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GOMF_ACTIN_BINDING, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_24HR, GOBP_PROTEIN_CATABOLIC_PROCESS, GOCC_TRANSFERASE_COMPLEX, GOBP_PROTEOLYSIS, GOCC_CULLIN_RING_UBIQUITIN_LIGASE_COMPLEX

GO Biological Process (1): proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)

GO Molecular Function (3): actin binding (GO:0003779), ubiquitin-like ligase-substrate adaptor activity (GO:1990756), protein binding (GO:0005515)

GO Cellular Component (4): cytoplasm (GO:0005737), actin cytoskeleton (GO:0015629), Cul3-RING ubiquitin ligase complex (GO:0031463), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
cytoskeletal protein binding	1
enzyme-substrate adaptor activity	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoskeleton	1
cullin-RING ubiquitin ligase complex	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

486 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IPP	MINPP1	Q9UNW1	881
IPP	CYB561A3	Q8NBI2	560
IPP	ZNF836	Q6ZNA1	524
IPP	POLR3H	Q9Y535	484
IPP	PIGL	Q9Y2B2	477
IPP	KLHDC1	Q8N7A1	404
IPP	CPPED1	Q9BRF8	402
IPP	OLFML2A	Q68BL7	392
IPP	PLA2G12A	Q9BZM1	380
IPP	PHYH	O14832	379
IPP	ENDOD1	O94919	375
IPP	RPL6	Q02878	370
IPP	UQCRB	P14927	368
IPP	MRPL41	Q8IXM3	364
IPP	STK35	Q8TDR2	360

IntAct

44 interactions, top by confidence:

A	B	Type	Score
PEF1	PDCD6	psi-mi:“MI:0914”(association)	0.900
KLHL12	KLHL2	psi-mi:“MI:0914”(association)	0.850
KLHL26	CUL3	psi-mi:“MI:0914”(association)	0.730
KLHL24	CUL3	psi-mi:“MI:0914”(association)	0.730
KLHL21	CUL3	psi-mi:“MI:0914”(association)	0.640
CUL3	ENC1	psi-mi:“MI:0914”(association)	0.640
KLHL22	METTL15	psi-mi:“MI:0914”(association)	0.640
KLHL9	ENC1	psi-mi:“MI:0914”(association)	0.640
ZNF517	GGPS1	psi-mi:“MI:0914”(association)	0.530
CUL3	ZSWIM8	psi-mi:“MI:0914”(association)	0.530
TACC3	HSPA8	psi-mi:“MI:0914”(association)	0.530
KLHL9	KLHL26	psi-mi:“MI:0914”(association)	0.530
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
KLHL20	KRBA1	psi-mi:“MI:0914”(association)	0.350
CUL3	KLHL2	psi-mi:“MI:0914”(association)	0.350
KLHL28	PRKACB	psi-mi:“MI:0914”(association)	0.350
LANCL1	MYO7A	psi-mi:“MI:0914”(association)	0.350
FERMT3	FERMT2	psi-mi:“MI:0914”(association)	0.350
MAPK1	SEC16A	psi-mi:“MI:0914”(association)	0.350
KLHL12	SKP1	psi-mi:“MI:0914”(association)	0.350
FBXL17	ZBTB5	psi-mi:“MI:0914”(association)	0.350
FBXL17	ENC1	psi-mi:“MI:0914”(association)	0.350
DNAL4	WDR91	psi-mi:“MI:0914”(association)	0.350
BACH2	ENC1	psi-mi:“MI:0914”(association)	0.350
OVOL2	TNPO2	psi-mi:“MI:0914”(association)	0.350
MAPK1	SPAG9	psi-mi:“MI:0914”(association)	0.350
COL16A1	PLOD3	psi-mi:“MI:0914”(association)	0.350
ZNF777	PTCD1	psi-mi:“MI:0914”(association)	0.350

BioGRID (64): IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS), IPP (Affinity Capture-MS)

ESM2 similar proteins: A0A2R8Q1W5, A6QQY2, B0WWP2, B3NDN0, B4HIK1, B4L0G9, B4LIG6, B4PD06, D3Z8N4, E0CZ16, E1B932, E7F6F9, E9Q4F2, F1LZ52, O94889, P28575, P57790, P59280, Q08DK3, Q14145, Q16RL8, Q2T9Z7, Q53G59, Q5R774, Q5R7B8, Q5U374, Q5ZKD9, Q5ZLD3, Q684M4, Q6DFF6, Q6JEL2, Q6JEL3, Q6NRH0, Q6TDP3, Q6TDP4, Q6ZPT1, Q7QGL0, Q80TF4, Q8BZM0, Q8K430

Diamond homologs: A0A1B8YAB1, A1YPR0, B0WWP2, B1H285, B3M9V8, B3NDN0, B4GRJ2, B4HIK1, B4J045, B4L0G9, B4LIG6, B4MXW3, B4PD06, B4QLQ2, C9JR72, D3Z8N4, E0CZ16, G3X9X1, O15062, O88939, O93567, O95365, P28575, P41182, P41183, Q08CL3, Q08DK3, Q13105, Q16RL8, Q2M0J9, Q3UQV5, Q52KB5, Q5EXX3, Q5R7B8, Q5RDY3, Q5TC79, Q5ZI33, Q5ZKD9, Q5ZM39, Q60821

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 51 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Class I MHC mediated antigen processing & presentation	6	13.6×	9e-04
Neddylation	7	10.7×	9e-04
Antigen processing: Ubiquitination & Proteasome degradation	7	8.4×	2e-03
Adaptive Immune System	7	6.7×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
integrin-mediated signaling pathway	5	16.7×	7e-04
endoplasmic reticulum to Golgi vesicle-mediated transport	5	14.2×	1e-03
proteasome-mediated ubiquitin-dependent protein catabolic process	12	13.0×	3e-08
protein ubiquitination	11	9.5×	3e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	79
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1782 predictions. Top by Δscore:

Variant	Effect	Δscore
1:45714245:CCT:C	donor_gain	1.0000
1:45714362:CCAT:C	acceptor_gain	1.0000
1:45714363:C:T	acceptor_gain	1.0000
1:45714363:CAT:C	acceptor_gain	1.0000
1:45716891:TTA:T	donor_loss	1.0000
1:45716892:TAC:T	donor_loss	1.0000
1:45716894:CCTTG:C	donor_gain	1.0000
1:45716951:T:TA	donor_gain	1.0000
1:45716952:C:A	donor_gain	1.0000
1:45717013:TCCAC:T	acceptor_gain	1.0000
1:45717014:CCAC:C	acceptor_gain	1.0000
1:45717014:CCACC:C	acceptor_gain	1.0000
1:45717015:CAC:C	acceptor_gain	1.0000
1:45717015:CACC:C	acceptor_gain	1.0000
1:45717015:CACCT:C	acceptor_loss	1.0000
1:45717016:AC:A	acceptor_gain	1.0000
1:45717016:ACCTG:A	acceptor_loss	1.0000
1:45717017:CC:C	acceptor_gain	1.0000
1:45717018:C:CC	acceptor_gain	1.0000
1:45719232:CACA:C	donor_gain	1.0000
1:45719234:CA:C	donor_gain	1.0000
1:45719235:A:AC	donor_gain	1.0000
1:45719236:C:CC	donor_gain	1.0000
1:45727625:TATTA:T	donor_loss	1.0000
1:45727627:TTACC:T	donor_loss	1.0000
1:45727628:TA:T	donor_loss	1.0000
1:45727630:C:CG	donor_loss	1.0000
1:45727669:C:CA	donor_gain	1.0000
1:45727795:CCAC:C	acceptor_gain	1.0000
1:45727796:CAC:C	acceptor_gain	1.0000

AlphaMissense

3819 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:45719281:A:G	W370R	1.000
1:45719281:A:T	W370R	1.000
1:45700025:A:G	W566R	0.999
1:45700025:A:T	W566R	0.999
1:45700046:A:C	Y559D	0.999
1:45716953:C:A	W417C	0.999
1:45716953:C:G	W417C	0.999
1:45716955:A:G	W417R	0.999
1:45716955:A:T	W417R	0.999
1:45717014:C:T	G397E	0.999
1:45719279:C:A	W370C	0.999
1:45719279:C:G	W370C	0.999
1:45727633:C:T	G349E	0.999
1:45727712:A:G	W323R	0.999
1:45727712:A:T	W323R	0.999
1:45727735:C:G	R315P	0.999
1:45741006:A:G	W207R	0.999
1:45741006:A:T	W207R	0.999
1:45741285:C:G	A114P	0.999
1:45700023:C:A	W566C	0.998
1:45700023:C:G	W566C	0.998
1:45714304:C:T	G491E	0.998
1:45714314:A:C	Y488D	0.998
1:45714448:C:T	G443E	0.998
1:45714449:C:A	G443W	0.998
1:45719250:C:G	R380P	0.998
1:45719340:C:T	G350D	0.998
1:45741077:A:G	L183P	0.998
1:45741284:G:T	A114E	0.998
1:45699994:C:G	R576P	0.997

dbSNP variants (sampled 300 via entrez): RS1000011065 (1:45709057 GA>G,GAA), RS1000013616 (1:45696316 C>A,G,T), RS1000129756 (1:45740145 T>C), RS1000193583 (1:45742240 T>G), RS1000222642 (1:45740558 C>A,G), RS1000316062 (1:45722948 G>A), RS1000406623 (1:45713031 G>A), RS1000523538 (1:45734671 G>A), RS1000546788 (1:45744856 T>A,G), RS1000587567 (1:45735366 G>A), RS1000654230 (1:45733576 C>T), RS1000733512 (1:45705761 GC>G,GCC), RS1000765921 (1:45744658 G>A), RS1000769671 (1:45727166 C>A), RS1000860229 (1:45724821 G>A,C,T)

Disease associations

OMIM: gene MIM:147485 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST004571_9	Iron status biomarkers (total iron binding capacity)	2.000000e-07
GCST004572_21	Iron status biomarkers (transferrin saturation)	2.000000e-07
GCST005951_37	Body mass index	8.000000e-10
GCST005991_75	Platelet count	2.000000e-10
GCST010083_240	Hemoglobin levels	2.000000e-20
GCST010696_7	Cortical thickness (min-P)	3.000000e-08
GCST010697_28	Cortical surface area (min-P)	2.000000e-08
GCST010698_30	Subcortical volume (min-P)	3.000000e-08
GCST010699_45	Brain morphology (min-P)	3.000000e-08
GCST010700_23	Cortical thickness (MOSTest)	1.000000e-10
GCST010701_9	Cortical surface area (MOSTest)	2.000000e-08
GCST010702_139	Subcortical volume (MOSTest)	4.000000e-14
GCST010703_258	Brain morphology (MOSTest)	2.000000e-13
GCST010988_531	Adult body size	4.000000e-14
GCST012020_65	Serum metabolite levels	1.000000e-17

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0006334	total iron binding capacity
EFO:0004340	body mass index
EFO:0004309	platelet count
EFO:0004509	hemoglobin measurement
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	6
trichostatin A	decreases expression, affects expression, affects cotreatment	4
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
GSK-J4	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
butyraldehyde	decreases expression	1
cupric oxide	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Resveratrol	increases expression, affects cotreatment	1
Temozolomide	decreases expression	1
Leflunomide	decreases expression	1
Cadmium	increases expression, increases abundance	1
Cisplatin	affects cotreatment, increases expression	1
Ethyl Methanesulfonate	increases expression	1
Hydrogen Peroxide	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Nickel	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Silicon Dioxide	decreases expression	1
Thiram	decreases expression	1
Urethane	decreases expression	1
Vitamin E	decreases expression	1
Cyclosporine	decreases expression	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.